49 Spam-Free Article(s) Found
Article Searches
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now http://www.zacks.com/stock/news/857564/3-stocks-immune-to-the-coronavirus-downturn-to-buy-right-now?cid=CS-ZC-FT-zacks_friday_finish_line-857564 Apr 06, 2020 - Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
Why the Earnings Surprise Streak Could Continue for Lilly (LLY) http://www.zacks.com/stock/news/857355/why-the-earnings-surprise-streak-could-continue-for-lilly-lly?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-857355 Apr 06, 2020 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes http://www.zacks.com/stock/news/857383/novo-nordisks-rybelsus-gets-eu-nod-for-type-ii-diabetes?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-857383 Apr 06, 2020 - Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/852982/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-852982 Apr 03, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates http://www.zacks.com/stock/news/853058/pharma-stock-roundup-jnj-snys-coronavirus-product-development-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-853058 Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day http://www.zacks.com/stock/news/851380/lly-oxm-amag-mist-and-cpix-as-zacks-bull-and-bear-of-the-day?cid=CS-ZC-FT-press_releases-851380 Apr 02, 2020 - LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
Top Analyst Reports for Eli Lilly, Charter Communications & Eaton http://www.zacks.com/research-daily/851105/top-analyst-reports-for-eli-lilly-charter-communications-eaton?cid=CS-ZC-FT-research_daily-851105 Apr 02, 2020 - Top Analyst Reports for Eli Lilly, Charter Communications & Eaton
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-ZC-FT-analyst_blog|rank_focused-851267 Apr 02, 2020 - Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA http://www.zacks.com/stock/news/849395/bristol-myers-bluebird-submit-bla-for-myeloma-drug-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-849395 Apr 01, 2020 - Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes http://www.zacks.com/stock/news/849056/3-drugmakers-still-worth-betting-on-amid-coronavirus-woes?cid=CS-ZC-FT-analyst_blog|investment_ideas-849056 Apr 01, 2020 - Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Pages: 12345

<<<Page 4